RU2017130289A3 - - Google Patents

Download PDF

Info

Publication number
RU2017130289A3
RU2017130289A3 RU2017130289A RU2017130289A RU2017130289A3 RU 2017130289 A3 RU2017130289 A3 RU 2017130289A3 RU 2017130289 A RU2017130289 A RU 2017130289A RU 2017130289 A RU2017130289 A RU 2017130289A RU 2017130289 A3 RU2017130289 A3 RU 2017130289A3
Authority
RU
Russia
Application number
RU2017130289A
Other languages
Russian (ru)
Other versions
RU2017130289A (ru
RU2722641C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017130289A publication Critical patent/RU2017130289A/ru
Publication of RU2017130289A3 publication Critical patent/RU2017130289A3/ru
Application granted granted Critical
Publication of RU2722641C2 publication Critical patent/RU2722641C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017130289A 2015-02-10 2015-09-22 Ценикривирок для лечения заболеваний печени и перитонита RU2722641C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114304P 2015-02-10 2015-02-10
US62/114,304 2015-02-10
PCT/US2015/051467 WO2016130179A1 (en) 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis

Publications (3)

Publication Number Publication Date
RU2017130289A RU2017130289A (ru) 2019-03-12
RU2017130289A3 true RU2017130289A3 (enExample) 2019-04-22
RU2722641C2 RU2722641C2 (ru) 2020-06-02

Family

ID=56614560

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017130289A RU2722641C2 (ru) 2015-02-10 2015-09-22 Ценикривирок для лечения заболеваний печени и перитонита

Country Status (15)

Country Link
US (3) US20180110754A1 (enExample)
EP (1) EP3256124B1 (enExample)
JP (2) JP6676660B2 (enExample)
KR (1) KR20170113596A (enExample)
CN (1) CN107405403B (enExample)
AU (1) AU2015382376B2 (enExample)
BR (1) BR112017016388A2 (enExample)
CA (1) CA2975445A1 (enExample)
ES (1) ES2864767T3 (enExample)
HK (1) HK1247558A1 (enExample)
IL (1) IL253617A0 (enExample)
MX (1) MX2017010277A (enExample)
RU (1) RU2722641C2 (enExample)
SG (1) SG11201706028RA (enExample)
WO (1) WO2016130179A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE539062T1 (de) 2001-08-08 2012-01-15 Tobira Therapeutics Inc Bizyklishe verbindung, ihre herstellung und verwendung
US10526349B2 (en) 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs
BR112018076449A2 (pt) 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞,其制备方法及抗纤维化的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
ATE539062T1 (de) 2001-08-08 2012-01-15 Tobira Therapeutics Inc Bizyklishe verbindung, ihre herstellung und verwendung
US20080031942A1 (en) 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
EP2723360B1 (en) * 2011-06-27 2017-05-31 Université Pierre et Marie Curie (Paris 6) Ccr2 antagonist peptides
JP6263814B2 (ja) * 2013-03-05 2018-01-24 国立大学法人 岡山大学 細胞死抑制剤及び新規化合物
MX383706B (es) * 2013-05-15 2025-03-14 Tobira Therapeutics Inc Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물

Also Published As

Publication number Publication date
EP3256124A4 (en) 2018-09-26
KR20170113596A (ko) 2017-10-12
CN107405403A (zh) 2017-11-28
IL253617A0 (en) 2017-09-28
AU2015382376B2 (en) 2021-07-01
ES2864767T3 (es) 2021-10-14
HK1247558A1 (zh) 2018-09-28
US20190343806A1 (en) 2019-11-14
WO2016130179A1 (en) 2016-08-18
CN107405403B (zh) 2021-04-20
JP2020111586A (ja) 2020-07-27
JP2018505218A (ja) 2018-02-22
US20200360347A1 (en) 2020-11-19
EP3256124A1 (en) 2017-12-20
RU2017130289A (ru) 2019-03-12
US20180110754A1 (en) 2018-04-26
JP6676660B2 (ja) 2020-04-08
AU2015382376A1 (en) 2017-08-17
RU2722641C2 (ru) 2020-06-02
EP3256124B1 (en) 2020-12-23
CA2975445A1 (en) 2016-08-18
SG11201706028RA (en) 2017-08-30
MX2017010277A (es) 2017-12-07
BR112017016388A2 (pt) 2018-03-27

Similar Documents

Publication Publication Date Title
BR112018004840A2 (enExample)
AU2022228198B1 (enExample)
BR202015019456U2 (enExample)
BE2015C047I2 (enExample)
BE2015C044I2 (enExample)
BR0007672B1 (enExample)
BR0007747B1 (enExample)
BR0009349B1 (enExample)
BR0002033B1 (enExample)
BR0009182B1 (enExample)
BR0008874B1 (enExample)
BR0008789B1 (enExample)
BR0008719B1 (enExample)
BR0001810B1 (enExample)
BR0001684B1 (enExample)
BR0008604B1 (enExample)
BR0001536B1 (enExample)
BR0008158B1 (enExample)
BR0006854B1 (enExample)
BR0007834B1 (enExample)
BR0006866B1 (enExample)
BR0000763F1 (enExample)
BR0007688B1 (enExample)
BR0000695B1 (enExample)
BR0002435B1 (enExample)